Skip to Main Content

A coalition of consumer groups and unions have asked the Federal Trade Commission to block AbbVie (ABBV) from proceeding with its proposed $63 billion acquisition of Allergan (AGN) in order “to prevent further harm to consumers.”

In arguing their case, the groups contend pharmaceutical industry has become increasingly concentrated, which has often caused higher prices and reduced choices. Moreover, they also maintained both companies have “engaged in a wide variety of anticompetitive conduct to stifle competition including restrictive contracting practices and intellectual property abuse.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!